EPZM Epizyme Inc.

22.41
+0.6  (+3%)
Previous Close 21.81
Open 21.98
Price To Book 7.97
Market Cap 2,190,367,048
Shares 97,740,609
Volume 552,569
Short Ratio
Av. Daily Volume 1,203,764
Stock charts supplied by TradingView

NewsSee all news

  1. Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma

    First and Only EZH2 Inhibitor Approved by the U.S. Food and Drug Administration U.S. Commercial Launch Underway Company to Host Conference Call Tonight at 5:30 p.m. ET Epizyme, Inc. (NASDAQ:EPZM), a

  2. Synovial Sarcoma Treatment Market will Experience a Noticeable growth During the Forecast Period 2019 – 2024

    HTF Market Intelligence/Press Release/- This intelligence report provides a comprehensive analysis of the Synovial Sarcoma Treatment Market. This includes Investigation of past progress, ongoing market scenarios, and

  3. Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value

    Additional Capital Further Extends Company's Operating Runway into 2022 Commercially Prepared to Launch Tazemetostat for Epithelioid Sarcoma; PDUFA Date Set for January 23, 2020 Epizyme, Inc. (NASDAQ:EPZM), a

  4. Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Follicular Lymphoma

    Submission Marks On-time Execution of Second NDA Submission for Tazemetostat in 2019 Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it

  5. Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 dosing commenced August 2016. Noted April 23, 2018 that all Tazemetostat trials have been placed on partial clinical hold.
Tazemetostat
Adult patients with mesothelioma characterized by BAP1 loss-of-function
NDA filing announced December 18, 2019.
Tazemetostat
Follicular lymphoma
FDA approval announced January 23, 2020.
Tazemetostat
Epithelioid Sarcoma
Phase 1b enrollment complete.
Tazemetostat + Atezolizumab
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Latest News

  1. Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma

    First and Only EZH2 Inhibitor Approved by the U.S. Food and Drug Administration U.S. Commercial Launch Underway Company to Host Conference Call Tonight at 5:30 p.m. ET Epizyme, Inc. (NASDAQ:EPZM), a

  2. Synovial Sarcoma Treatment Market will Experience a Noticeable growth During the Forecast Period 2019 – 2024

    HTF Market Intelligence/Press Release/- This intelligence report provides a comprehensive analysis of the Synovial Sarcoma Treatment Market. This includes Investigation of past progress, ongoing market scenarios, and

  3. Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value

    Additional Capital Further Extends Company's Operating Runway into 2022 Commercially Prepared to Launch Tazemetostat for Epithelioid Sarcoma; PDUFA Date Set for January 23, 2020 Epizyme, Inc. (NASDAQ:EPZM), a

  4. Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Follicular Lymphoma

    Submission Marks On-time Execution of Second NDA Submission for Tazemetostat in 2019 Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it

  5. Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration

  6. Epizyme (EPZM) Trading of Stock Halted; Oncology Drug Advisory Committee to Review Tazemetostat at 8:00 a.m. ET Today

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, announced today that trading of its common stock has been halted. The U.S. Food and Drug Administration's (FDA)

  7. Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma

    NDA Submission for Accelerated Approval of Tazemetostat for Patients with Relapsed or Refractory Follicular Lymphoma on Track for December 2019 Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company

  8. Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration

  9. Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme

    NEW YORK, Nov. 5, 2019 /PRNewswire/ -- Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s

  10. Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement

    $100 Million Upfront Investment by Royalty Pharma with Up to $100 Million in Future Equity Existing Royalty Obligation on Future Tazemetostat Sales Reduced with Royalty Pharma $70 Million Expandable Loan Facility

  11. Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results

    Pre-NDA Meeting Supports Registration Strategy for Tazemetostat for Follicular Lymphoma Patients with and without EZH2 Activating Mutations and Planned NDA Submission in December 2019 Updated Phase 2 Follicular

  12. Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointments of experienced commercial executive, Grant Bogle, and research and development

  13. Epizyme to Participate in Upcoming September Conferences

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in the following